Precision Antibody & A&G Pharmaceutical to Participate in Targeted Therapies Licensing & Partnering

COLUMBIA, Md. - EntSun -- Precision Antibody, a leader in custom monoclonal antibody development, announces its participation in the Targeted Therapies Licensing & Partnering Summit Asia 2026, taking place February 26–27, 2026, in Meguro-ku, Tokyo, Japan.

Precision Antibody will attend the partnering-focused meeting alongside A&G Pharmaceutical, Inc., engaging with biopharmaceutical companies, investors, and research leaders to explore strategic collaborations in targeted therapies and antibody-based drug development.

The Targeted Therapies Licensing & Partnering Summit Asia is a premier event designed to facilitate high-value business development discussions, licensing opportunities, and cross-border partnerships within oncology and precision medicine. The summit provides a dedicated platform for companies advancing innovative therapeutic assets to connect with potential partners across Asia and globally.

More on EntSun News

• Special Alert: Undervalued Opportunity: IQSTEL (N A S D A Q: IQST) Positioned for Explosive Multi-Year Growth
• Triple-Digit Growth, Strategic N A S D A Q Uplist, Plus A Scalable Healthcare Rollout Model: Stock Symbol: CDIX
• Vesica Health Receives FDA Breakthrough Device Designation for AssureMDx
• Cygnet Theatre Announces The Cast And Creative Team Of Stefano Massini's The Lehman Trilogy
• Lineus Medical's SafeBreak® Vascular Added to Alliant GPO Contract

Precision Antibody brings to the meeting its extensive expertise in custom monoclonal antibody development, including fully human antibody generation and biomarker-focused antibody solutions that support therapeutic and translational research initiatives.

"Partnering meetings like this play a critical role in accelerating innovation," said Dr. Serrero. "We look forward to engaging with potential collaborators in Tokyo and exploring opportunities to advance targeted therapy programs through strategic partnerships."

As biomarker antibody specialists, Precision Antibody has established a strong track record in developing high-quality, high-affinity monoclonal antibodies for oncology research. The company is also a proud contributor to the National Cancer Institute's Clinical Proteomic Technologies for Cancer (CPTC) program through Leidos, helping establish gold-standard monoclonal antibodies widely used in cancer biomarker research.

More on EntSun News

• Cancun All Inclusive is ready for Spring Break 2026 with new Resorts, Exclusive Deals, activities and more!
• "EntryLevelActing.LA 2026 Promo" World Premieres in Hollywood's TCL Chinese Theatre 6pm PST 3/3/26
• 66% of US Bankruptcies Are Medical — So Americans Are Building Businesses That Cover Healthcare Emergencies
• iPOP Alum Madison Wolfe to Star in Ari Schlossberg's Upcoming Thriller "Young Blood"
• Ludex Partners With Certified Trading Card Association (CTCA) To Elevate Standards And Innovation In The Trading Card Industry

Through its collaboration-driven approach and commitment to scientific excellence, Precision Antibody continues to support biopharma partners in accelerating the discovery and development of next-generation targeted therapeutics.

Attendees of the Targeted Therapies Licensing & Partnering Summit Asia 2026 are invited to connect with representatives from Precision Antibody and A&G Pharmaceutical to discuss licensing opportunities, co-development partnerships, and strategic collaborations.

Event Details:

Targeted Therapies Licensing & Partnering Summit Asia 2026
Dates: February 26–27, 2026
Location: Meguro-ku, Tokyo, Japan
Event Website: https://targeted-therapies-asia.com/